Trial Profile

A Phase 1 Study of AG-636 in the Treatment of Subjects With Advanced Lymphoma

Status: Discontinued

Phase of Trial: Phase I

Latest Information Update: 26 Aug 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AG 636 (Primary)
Indications B-cell lymphoma; Cutaneous T-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Hodgkin's disease; Lymphoma; Lymphoproliferative disorders; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; Peripheral T-cell lymphoma; T-cell lymphoma
Focus Adverse reactions; First in man
Sponsors Agios Pharmaceuticals

Most Recent Events

21 Aug 2020 Status changed from active, no longer recruiting to discontinued due to sponsor decision.
03 Jun 2020 Status changed from recruiting to active, no longer recruiting.
30 Apr 2020 According to an Agios Pharmaceuticals media release, as a result of limited enrollment in the study, the company will stop in-house development of AG-636 and evaluate partnering options.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com